In some cancers where there is a mutant kinase driving the proliferation of the tumor cell by activating the MAPK pathway, such as mutant EGFR in NSCLC or BRAF(V600E) melanoma, vertical pathway combination kinase inhibitors maybe successful therapies in some patients. The gene discussed is BRAF; the disease is neoplasm.